Sense and nonsense in sensors

Continuous subcutaneous glucose monitoring (CGM) is a developing technology in the treatment of diabetes mellitus. The first randomised controlled trials on its efficacy have been performed. In several studies, CGM lowered HbA(1c) in adult patients with suboptimally controlled type 1 diabetes mellit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermanides, J., DeVries, J. H.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830625/
https://www.ncbi.nlm.nih.gov/pubmed/20225392
http://dx.doi.org/10.1007/s00125-009-1649-4
Descripción
Sumario:Continuous subcutaneous glucose monitoring (CGM) is a developing technology in the treatment of diabetes mellitus. The first randomised controlled trials on its efficacy have been performed. In several studies, CGM lowered HbA(1c) in adult patients with suboptimally controlled type 1 diabetes mellitus, when selecting compliant patients who tolerate the device. However, as a preventive tool for hypoglycaemia, CGM has not fulfilled the great expectations. Increasing reimbursement of CGM is expected in the near future, awaiting studies on cost-effectiveness.

Ejemplares similares